Artemis Medicare Services Ltd
Artemis Medicare Services Ltd (AMSL) was incorporated on 2004, by the promoters of the Apollo Tyres Group, is engaged in healthcare business. AMSL operates a 541-bedded multi-specialty tertiary care hospital in Gurgaon. The specialty areas for AMSL include Orthopaedics, Oncology, Cardiovascular, Neurosciences and Bariatric & Minimally Invasive Surgery. ASML has been awarded with the NABH and JCI accreditation. AMSL has also diversified its presence through Artemis Daffodil , Artemis Lite, Artemis Cardiac Care and Artemis Solace models. [1][2]
- Market Cap ₹ 3,854 Cr.
- Current Price ₹ 280
- High / Low ₹ 305 / 141
- Stock P/E 69.1
- Book Value ₹ 33.0
- Dividend Yield 0.16 %
- ROCE 13.6 %
- ROE 11.5 %
- Face Value ₹ 1.00
Pros
Cons
- Stock is trading at 8.49 times its book value
- Company has a low return on equity of 10.3% over last 3 years.
- Promoters have pledged 44.5% of their holding.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Part of BSE Healthcare BSE SmallCap BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|
547 | 565 | 408 | 555 | 737 | 879 | 892 | |
481 | 503 | 373 | 487 | 643 | 746 | 751 | |
Operating Profit | 66 | 62 | 35 | 68 | 94 | 133 | 141 |
OPM % | 12% | 11% | 9% | 12% | 13% | 15% | 16% |
2 | 4 | 7 | 3 | 7 | 7 | 10 | |
Interest | 11 | 13 | 13 | 12 | 20 | 31 | 33 |
Depreciation | 20 | 23 | 22 | 22 | 31 | 40 | 42 |
Profit before tax | 37 | 31 | 8 | 37 | 51 | 68 | 77 |
Tax % | 45% | 36% | 18% | 16% | 25% | 28% | |
20 | 19 | 6 | 31 | 38 | 49 | 56 | |
EPS in Rs | 0.97 | 1.49 | 0.49 | 2.40 | 2.88 | 3.62 | 4.11 |
Dividend Payout % | 0% | 0% | 0% | 0% | 16% | 12% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 10% |
3 Years: | 29% |
TTM: | 14% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 18% |
3 Years: | 103% |
TTM: | 42% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 98% |
1 Year: | 68% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 8% |
3 Years: | 10% |
Last Year: | 12% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
Equity Capital | 13 | 13 | 13 | 13 | 13 | 14 |
Reserves | 280 | 300 | 307 | 346 | 390 | 435 |
114 | 113 | 147 | 201 | 286 | 320 | |
147 | 160 | 133 | 149 | 216 | 203 | |
Total Liabilities | 554 | 586 | 600 | 710 | 905 | 972 |
381 | 393 | 383 | 489 | 605 | 719 | |
CWIP | 49 | 56 | 81 | 64 | 95 | 33 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 |
124 | 137 | 136 | 157 | 205 | 219 | |
Total Assets | 554 | 586 | 600 | 710 | 905 | 972 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
40 | 56 | 27 | 60 | 127 | 109 | |
-50 | -26 | -37 | -107 | -158 | -87 | |
14 | -27 | 18 | 44 | 38 | -30 | |
Net Cash Flow | 5 | 2 | 8 | -3 | 7 | -8 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
Debtor Days | 52 | 49 | 49 | 48 | 46 | 39 |
Inventory Days | ||||||
Days Payable | ||||||
Cash Conversion Cycle | 52 | 49 | 49 | 48 | 46 | 39 |
Working Capital Days | -26 | -28 | -16 | -9 | -26 | -13 |
ROCE % | 10% | 4% | 10% | 11% | 14% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Investor Presentation
7m - Earnings Presentation - Q2 and H1 FY25
- Announcement under Regulation 30 (LODR)-Newspaper Publication 2h
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)
2h - Artemis reports Q2 FY25 results with highest revenue.
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
22h - Monitoring Agency Report for Q2 FY2025 submitted.
-
Statement Of Deviation Or Variation- Quarter Ended September 30, 2024
22h - No deviation in use of funds from preferential issue.
Geographical Revenue Break-up 9MFY24:[1]
Domestic : ~76%
Outside India : ~24%